Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 676 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Valve Heart Disease Clear all

Conditions: Tricuspid Regurgitation (TR)
Interventions: TRiCares Topaz TTVR System, Edwards EVOQUE TTVR System; Device
Lead sponsor: TRiCares; Industry
Eligibility: 18 Years and older
Enrollment: 831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Mitral Valve Prolapse
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myocardial Infarction, Coronary Artery Bypass, Percutaneous Coronary Intervention, Heart Failure, Cardiac Valve Surgery
Interventions: RPE (usual care), GXT+THHR (intervention); Behavioral
Lead sponsor: Baystate Medical Center; Other
Eligibility: 60 Years to 99 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Springfield, Massachusetts • Detroit, Michigan

Conditions: Mitral Valve Regurgitation
Interventions: Mitral valve repair, Transcatheter edge-to-edge repair; Procedure · Device
Lead sponsor: Annetine Gelijns; Other
Eligibility: 60 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 19 more

Conditions: Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Interventions: Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline; Drug · Device
Lead sponsor: Heart Metabolics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Stanford, California • Indianapolis, Indiana • Baltimore, Maryland + 7 more

Conditions: Mitral Valve Regurgitation, Left Ventricular Dysfunction, Heart Failure, Mitral Insufficiency, Mitral Incompetence, Ischemic Heart Disease
Interventions: Percutaneous mitral valve repair; Device
Lead sponsor: Myocor; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Atlanta, Georgia • Evanston, Illinois • Shawnee Mission, Kansas + 1 more

Conditions: Williams Syndrome, Lipedema
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Valve Disease
Interventions: On-X Heart valve replacement, SJM Heart valve replacement; Device
Lead sponsor: On-X Life Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 857 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Honolulu, Hawaii • St Louis, Missouri + 3 more

Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction, Systolic Anterior Motion
Interventions: SESAME Procedure; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Early Repolarization Syndrome (ERS), Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Normal Control Subjects
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions: Warfarin GenoSTAT Test; Device
Lead sponsor: Iverson Genetic Diagnostics, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 3,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 56
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Aortic Valve Disease, Aortic Valve Stenosis
Interventions: Foldax Tria Aortic Valve; Device
Lead sponsor: Foldax, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Indianapolis, Indiana • Wichita, Kansas • Detroit, Michigan + 2 more

Conditions: Tricuspid Valve Insufficiency
Interventions: TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty); Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Atlanta, Georgia • Roslyn, New York

Conditions: Left Ventricular Dysfunction, Right Ventricular Dysfunction, Pulmonary Hypertension, Heart Valve Diseases
Interventions: Not listed
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Tetrology of Fallot, Pulmonary Stenosis, Truncus Arteriosus, Transposition of Great Vessels, Pulmonary Atresia, Ross Procedure
Interventions: Surgical Right Ventricular Outflow Tract Reconstruction; Device
Lead sponsor: PECA Labs; Industry
Eligibility: 0 Years to 22 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Peoria, Illinois • Boston, Massachusetts • Cincinnati, Ohio + 2 more

Conditions: Aortic Valve Stenosis
Interventions: Ataciguat, Placebo; Drug
Lead sponsor: Jordan D. Miller, Ph.D.; Other
Eligibility: 50 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Williams Syndrome
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aortic Stenosis
Interventions: SAPIEN S3 valve; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 1,822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 55
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 46 more

Conditions: Williams Syndrome, Anxiety
Interventions: Buspirone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Aortic Stenosis
Interventions: Shockwave M5 IVL Catheter, Modified Seldinger Technique; Device · Procedure
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Obstructive Hypertrophic Cardiomyopathy
Interventions: Mavacamten; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 21 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Mitral Regurgitation, Mitral Valve Regurgitation
Interventions: MitraClip® NT System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 32
States / cities: La Jolla, California • Los Angeles, California • Mountain View, California + 25 more

Search by objective public record fields.

The TRICURE US IDE Pivotal Study

Genetic Basis of Mitral Valve Prolapse

Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study

Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study

Prospective Randomized On-X Versus SJM Evaluation Trial

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Early Feasibility Study for the Foldax Tria Aortic Heart Valve

NHLBI and Cook Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty (TRAIPTA) Early Feasibility Study

A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System

MASA Valve Early Feasibility Study

Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis

Fat Distribution and Glucose Metabolism in Williams Syndrome

PARTNER II Trial: S3iCAP

Buspirone Treatment of Anxiety in Williams Syndrome

Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Ross Aortic Valve Replacement Patients

Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR